ArticleJournal of nanobiotechnology2025
Hollow spiky MnOx nanocarriers amplify radiotherapy-induced pyroptosis for eliciting antitumor immunity.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatially organized regulated cell death-immune coupling in solid tumors: integrating spatial omics with actionable regulated cell death biology.Molecular cancer · 2026Review
- A novel pH-responsive nanoreactor for pyroptosis induction: multifaceted ROS amplification drives potent immunotherapy against triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Radiotherapy (RT) is a primary modality in clinical cancer treatment. However, its ability to induce tumor cell apoptosis offers limited activation of anti-tumor immunity. Pyroptosis, characterized by cell swelling, membrane rupture, and the release of pro-inflammatory cytokines, has been demonstrated to potentiate immune responses against cancer cells. Herein, we develop hollow spiky manganese oxide (HSpiM) nanocarriers to enhance RT-induced tumor pyroptosis and elicit anti-tumor immune responses. The spiked structure of HSpiM nanocarriers promotes intracellular lysosomal rupture, while simultaneously producing elevated amounts of reactive oxygen species (ROS) after RT, to synergistically activate the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome. Notably, lysosomal rupture-induced autophagy inhibition amplifies NLRP3-mediated pyroptosis by blocking lysosome-mediated degradation pathways. Moreover, we encapsulate an ESCRT inhibitor, the Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.